Abstract
Alzheimer disease (ADa) is the most common form of senile dementia, and it is characterized pathologically by decreased brain mass. An important problem to inhibiting β-secretase, is to cross the blood-brain barrier (BBB) using drugs not derived from proteins and thus more efficient to design drugs to treat Alzheimers disease. In this sense, quantitative structure-activity relationships (QSAR) could play an important role in studying these β-secretase inhibitors. QSAR models are necessary in order to guide the β-secretase synthesis. In the present work, we firstly revised two servers like ChEMBL or PDB to obtain databases of β-secretase inhibitors. Next, we review previous works based on 2D-QSAR, 3DQSAR, CoMFA, CoMSIA and Docking techniques, which studied different compounds to find out the structural requirements. Last, we carried out new QSAR studies using Artificial Neural Network (ANN) method and the software Modes- Lab in order to understand the essential structural requirement for binding with receptor for β-secretase inhibitors.
Keywords: QSAR, CoMSIA, COMFA, docking, topological indices, β-secretase inhibitors, alzheimer's disease (AD), Romuald.Bellmann@i-med.ac.at, Lipinski Parameters,, Transport Protein, Glycerol Acetate ion, Glycerol, Protein transport hidrolase, triphloroethol, Lamarckian Genetic Algorithm
Current Bioinformatics
Title: Review of Bioinformatics and QSAR Studies of β-Secretase Inhibitors
Volume: 6 Issue: 1
Author(s): Francisco Prado-Prado, Manuel Escobar-Cubiella and Xerardo Garcia-Mera
Affiliation:
Keywords: QSAR, CoMSIA, COMFA, docking, topological indices, β-secretase inhibitors, alzheimer's disease (AD), Romuald.Bellmann@i-med.ac.at, Lipinski Parameters,, Transport Protein, Glycerol Acetate ion, Glycerol, Protein transport hidrolase, triphloroethol, Lamarckian Genetic Algorithm
Abstract: Alzheimer disease (ADa) is the most common form of senile dementia, and it is characterized pathologically by decreased brain mass. An important problem to inhibiting β-secretase, is to cross the blood-brain barrier (BBB) using drugs not derived from proteins and thus more efficient to design drugs to treat Alzheimers disease. In this sense, quantitative structure-activity relationships (QSAR) could play an important role in studying these β-secretase inhibitors. QSAR models are necessary in order to guide the β-secretase synthesis. In the present work, we firstly revised two servers like ChEMBL or PDB to obtain databases of β-secretase inhibitors. Next, we review previous works based on 2D-QSAR, 3DQSAR, CoMFA, CoMSIA and Docking techniques, which studied different compounds to find out the structural requirements. Last, we carried out new QSAR studies using Artificial Neural Network (ANN) method and the software Modes- Lab in order to understand the essential structural requirement for binding with receptor for β-secretase inhibitors.
Export Options
About this article
Cite this article as:
Prado-Prado Francisco, Escobar-Cubiella Manuel and Garcia-Mera Xerardo, Review of Bioinformatics and QSAR Studies of β-Secretase Inhibitors, Current Bioinformatics 2011; 6 (1) . https://dx.doi.org/10.2174/157489311795222428
DOI https://dx.doi.org/10.2174/157489311795222428 |
Print ISSN 1574-8936 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-392X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial [Hot Topic: Brain Resilience and Plasticity in the Face of Alzheimer Pathology (Guest Editor: Ira Driscoll & Juan Troncoso)]
Current Alzheimer Research Inflammatory Responses in Brain Ischemia
Current Medicinal Chemistry Unmasking Sex-Based Disparity in Neuronal Metabolism
Current Pharmaceutical Design Organelle Stress Sensors and Cell Death Mechanisms in Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Editorial [Hot Topic: Innate Immune Responses in CNS Neurodegenerative Diseases (Guest Editors: Hans van Noort and Sandra Amor)]
CNS & Neurological Disorders - Drug Targets The Prion-like Properties of Amyloid-beta Peptide and Tau: Is there Any Risk of Transmitting Alzheimer's Disease During Neurosurgical Interventions?
Current Alzheimer Research Astroglial Connexins as a Therapeutic Target for Alzheimer's Disease
Current Pharmaceutical Design Thromboembolic Complications in Malignant Haematological Disorders
Current Vascular Pharmacology The Role of MAPK's Signaling in Mediating ApoE4-Driven Pathology In Vivo
Current Alzheimer Research Magnesium Lithospermate B Extracted from Salvia Miltiorrhiza, A Potential Substitute for Cardiac Glycosides
Mini-Reviews in Organic Chemistry Novel Indole-Isoxazole Hybrids: Synthesis and In Vitro Anti-Cholinesterase Activity
Letters in Drug Design & Discovery Interventions to Reduce Cardiovascular Risk in Children with Type 1 Diabetes
Current Diabetes Reviews Metabolic Syndrome: Clinical Features Leading to Therapeutic Strategies
Vascular Disease Prevention (Discontinued) Therapeutic Hypothermia in Brain Injuries and Related Diseases
Recent Patents on Inflammation & Allergy Drug Discovery Motor and Non-Motor Features of Parkinson’s Disease – A Review of Clinical and Experimental Studies
CNS & Neurological Disorders - Drug Targets Neurological Disorders in Medical Use of <i>Cannabis</i>: An Update
CNS & Neurological Disorders - Drug Targets Platelets and Platelet Interaction with Progenitor Cells in Vascular Homeostasis and Inflammation
Current Vascular Pharmacology An Increase in Aβ42 in the Prefrontal Cortex is Associated with a Reversal-Learning Impairment in Alzheimers Disease Model Tg2576 APPsw Mice
Current Alzheimer Research The Two Faces of Iminoalditols: Powerful Inhibitors Trigger Glycosidase Activation
Current Enzyme Inhibition Alzheimer’s Disease Brain Areas: The Machine Learning Support for Blind Localization
Current Alzheimer Research